Roche sales boosted by Tamiflu but Genentech manoeuvre hits profits – update
This article was originally published in Scrip
Executive Summary
Roche has reported an 8% rise in 2009 sales to CHF49.1 billion ($46.6 billion), driven by sales of its influenza treatment Tamiflu (oseltamivir), its cancer portfolio and the age-related macular degeneration drug Lucentis (ranibizumab). However, the costs associated with its integration of Genentech dragged net income down by 22% to CHF8.5 billion.